Premessa e rilevanza
New trials and approvals of targeted and immune-oncologic therapies have enriched the options for first-line systemic therapy of advanced and metastatic ccRCC.
Questa versione in lingua รจ in sviluppo; le traduzioni verranno aggiunte progressivamente
New trials and approvals of targeted and immune-oncologic therapies have enriched the options for first-line systemic therapy of advanced and metastatic ccRCC.